Russell H Morgan Department of Radiology and Radiological Science, School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
J Cardiovasc Transl Res. 2010 Feb;3(1):24-9. doi: 10.1007/s12265-009-9158-x.
As clinical trials with stem cells for cardiac regenerative therapy move forward, advances in imaging equipment and technique offer powerful methods to evaluate therapeutic efficacy. Methodologies to label stem cells for tracking continue to expand. Non-invasive imaging offers the potential to better understand the interaction of exogenous stem cells with the host to answer questions such as the best cell type(s), timing of delivery, dose, and delivery route. If successful, these techniques may enable individually tailored dosing of stem cell therapeutics. However, techniques that are suitable for animal models of cardiac disease may have hurdles to clinical translation beyond simple biocompatibility issues. Challenges include the high cost of advanced imaging techniques, applicability in acute ischemic disease, and regulatory approval. In this review, we will cover some new imaging techniques and labeling strategies and assess the obstacles to clinical adoption.
随着干细胞心脏再生治疗的临床试验不断推进,成像设备和技术的进步为评估治疗效果提供了强大的方法。用于标记干细胞以进行追踪的方法不断扩展。非侵入性成像有可能更好地了解外源干细胞与宿主的相互作用,从而回答最佳细胞类型、递送时间、剂量和递送途径等问题。如果成功,这些技术可能使干细胞治疗的个体化给药成为可能。然而,适用于心脏病动物模型的技术在超越简单的生物相容性问题方面可能在临床转化方面存在障碍。挑战包括先进成像技术的高成本、在急性缺血性疾病中的适用性以及监管批准。在这篇综述中,我们将介绍一些新的成像技术和标记策略,并评估其临床应用的障碍。